Cargando…

Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review

Immune checkpoint inhibitors (ICIs) have demonstrated marked efficacy in some cancer patients, but they may cause various severe immune-related adverse events. Alectinib is a second-generation anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor (TKI) approved for ALK-rearranged non-small-cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishiyama, Akihiro, Hattori, Yoshihiro, Takeuchi, Shinji, Tanimoto, Azusa, Satouchi, Miyako, Murayama, Toshinori, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259316/ https://www.ncbi.nlm.nih.gov/pubmed/34803090 http://dx.doi.org/10.2169/internalmedicine.7472-21

Ejemplares similares

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET
por: Arai, Sachiko, et al.
Publicado: (2017)

Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
por: Tanimoto, Azusa, et al.
Publicado: (2014)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2021)

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
por: Adachi, Yuta, et al.
Publicado: (2020)

Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis
por: Yanagimura, Naohiro, et al.
Publicado: (2022)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass
por: Ohtsubo, Koushiro, et al.
Publicado: (2020)

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells
por: Suzuki, Chiaki, et al.
Publicado: (2022)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
por: Tanimoto, Azusa, et al.
Publicado: (2018)

Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
por: Kita, Kenji, et al.
Publicado: (2019)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma
por: Okumoto, Joe, et al.
Publicado: (2020)

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up
por: Pruis, Melinda A., et al.
Publicado: (2023)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
por: Peng, Shunli, et al.
Publicado: (2019)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
por: Yasuda, Yuichiro, et al.
Publicado: (2017)

Metabolites of alectinib in human: their identification and pharmacological activity
por: Sato-Nakai, Mika, et al.
Publicado: (2017)

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
por: Wang, Rong, et al.
Publicado: (2020)

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
por: Shimokawa, Mototsugu, et al.
Publicado: (2020)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Development of Alectinib-Suspended SNEDDS for Enhanced Solubility and Dissolution
por: Park, Eun Ji, et al.
Publicado: (2022)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
por: Sugiyama, Keiji, et al.
Publicado: (2021)

Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic Lymphomakinase-Positive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib
por: Katgı, Nuran, et al.
Publicado: (2023)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Patient-reported outcomes in a phase II study of alectinib
por: Ohe, Yuichiro
Publicado: (2018)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
por: Di Marino, Pietro, et al.
Publicado: (2020)

Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome
por: Farooq, Sahira, et al.
Publicado: (2020)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2o2ljjctip6trvb2s5st7hkk09